Posted by Michael Wonder on 01 Sep 2021
MicroTransponder receives FDA approval for breakthrough device benefiting stroke survivors
31 August 2021 - MicroTransponder today announced US FDA premarket approval of the Vivistim Paired VNS System, which significantly improves the effectiveness of rehabilitation therapy for stroke survivors with moderate to severe upper extremity impairment six months after stroke.
MicroTransponder's platform pairs vagus nerve stimulation with rehabilitation therapy to help improve stroke-related arm and hand deficits.
